(2nd article) FDA Safety Alerts for Human Medical Products > Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp)

Safety Concerns Prompt New Recommendations for Anemia Drugs « news@JAMA (patients with chronic kidney disease)

"The revised recommendations apply to epoetin alfa, which is marketed as Epogen and Procrit, and to darbepoetin alfa, marketed as Aranesp."

Randomized Phase 2 Dose-finding Study of Weekly Administration of Darbepoetin Alfa in Anemic Patients with Lung or Ovarian Cancer Receiving Multicycle Platinum-containing Chemotherapy